EP1773361B2 - Composition a base de bacteries probiotiques et son utilisation en vue de prevenir et/ou de traiter des pathologies et/ou des infections respiratoires et d'ameliorer la fonctionnalite intestinale - Google Patents

Composition a base de bacteries probiotiques et son utilisation en vue de prevenir et/ou de traiter des pathologies et/ou des infections respiratoires et d'ameliorer la fonctionnalite intestinale Download PDF

Info

Publication number
EP1773361B2
EP1773361B2 EP05793656A EP05793656A EP1773361B2 EP 1773361 B2 EP1773361 B2 EP 1773361B2 EP 05793656 A EP05793656 A EP 05793656A EP 05793656 A EP05793656 A EP 05793656A EP 1773361 B2 EP1773361 B2 EP 1773361B2
Authority
EP
European Patent Office
Prior art keywords
lactobacillus
bifidobacterium
composition
lmg
ssp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP05793656A
Other languages
German (de)
English (en)
Other versions
EP1773361A1 (fr
EP1773361B1 (fr
Inventor
Giovanni Mogna
Gian Paolo Strozzi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Probiotical SpA
Original Assignee
Probiotical SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35677517&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1773361(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Probiotical SpA filed Critical Probiotical SpA
Priority to PL05793656T priority Critical patent/PL1773361T5/pl
Publication of EP1773361A1 publication Critical patent/EP1773361A1/fr
Application granted granted Critical
Publication of EP1773361B1 publication Critical patent/EP1773361B1/fr
Publication of EP1773361B2 publication Critical patent/EP1773361B2/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Definitions

  • the present invention relates to probiotic bacteria based compositions, integrated with prebiotic substances, and the use thereof in the prevention and/or treatment of respiratory pathologies and/or infections and in the contemporaneous improvement of the intestinal functionality, which may result compromised from therapeutic treatments adopted for resolving said pathological conditions.
  • probiotic it is understood to mean those living species-specific microorganisms which, when swallowed or applied in a sufficient number, are able to induce in the consumer specific functional and beneficial effects on the state of health of the host.
  • the probiotic microorganism can be defined by the term "biotherapeutic agent", to testify the potential ability of supplying a valid help to the medical therapy. Therefore, considering that the beneficial properties of the probiotics can be both of a general systemic order and aimed to solve specific disorders or diseases, their use concerns various applicative fields, from the food industry to the pharmaceutical one.
  • the probiotic bacteria are usually employed, for example, in the prevention and treatment of intestinal pathologies of a different origin and nature.
  • the possible beneficial action of the probiotic bacteria is also object of study, for example in patients suffering from diabetes mellitus of type 2, chronic autoimmune and inflammatory pathologies, tumor pathologies, high serum levels of cholesterol.
  • probiotic bacteria in association, or not, with opportune substances having prebiotic properties for the prevention and/or treatment of respiratory pathologies and/or infections and, at the same time, for the improvement and/or the regularization of the intestinal functionality, which can result compromised (indeed, very often it results compromised) by therapeutic treatments adopted for resolving said pathological conditions, is not known.
  • the patent application DE 202 02 562 discloses a probiotic composition containing a micronutrient combination product, that comprises at least two product rates with different mixtures.
  • the above first product rate comprises active probiotic elements, while the second product rate comprises active prebiotic elements, vitamins and secondary plant compound.
  • the US patent application N.° 2003/180272 discloses an invention which is in the field of prophylaxis of allergies, and relates specifically to primary prevention of atopic diseases by administering probiotic bacteria, beneficial microbes of the healthy gut flora, pre- and postnatally to children at high risk of atopic diseases.
  • the patent application WO 01/97821 relates to compositions and methods for therapeutic or prophylactic treatment of disorders associated with mucosal surfaces and in particular to treatment of infectious disorders at mucosal sites by enhancing non-specific mucosal immunity, especially with probiotics such as lactobacillus or mycobacterium vaccae.
  • the respiratory pathologies and/or infections are treated by using the administration, sometimes also massive and for prolonged times, of antibiotics and/or antiinflamatories.
  • the object of the present invention is to prevent and/or therapeutically treat respiratory pathologies and/or infections of a various origin and nature, without causing undesired side effects, such as those induced by the traditional treatments with antibiotics and/or antiinflammatories.
  • Another of the objects of the present invention is to prevent and/or therapeutically treat respiratory pathologies and/or infections of a various origin and nature, by simultaneously improving and/o regularizing the intestinal functionality of the organism, often compromised by said pathological conditions.
  • the present invention therefore provides the use of a composition including a mixture of probiotic bacteria and at least a prebiotic fiber for the preparation of a medicament for the prevention and/or the therapeutic treatment of respiratory pathologies and/or infections, as defined in independent claim 1.
  • the present invention also provides a composition for the use above-mentioned, including a mixture of probiotic bacteria, belonging to the genus Lactoba cillus and genus Bifidobacterium, and at least a prebiotic fiber as defined in independent claim 5.
  • a kit for the co-ordinated administration of said composition in combination with one or more pharmacologically active substances, as defined in independent claim 14, is also provided.
  • composition of the present invention is also used for the preparation of a medicament for the prevention and/or the therapeutic treatment of respiratory pathologies and/or infections.
  • composition of the present invention is also used for the preparation of a medicament for the prevention and/or the therapeutic treatment of respiratory pathologies and/or infections, with a simultaneous improvement and/or regularization of the intestinal functionality of the organism.
  • composition of the present invention is also used for the preparation of a medicament for preventing and fighting infections caused by influenza.
  • composition of the present invention includes a mixture of three probiotic bacterial species, belonging to the genus Lactobacillus and the genus Bifidobacterium , as claimed.
  • composition of the present invention additionally includes at least a substance having prebiotic properties.
  • prebiotic are generally shown substances or components of the diet (such as, for example, fibres), neither digestible nor absorbable by the organism, which, when arrived integral in the colon, selectively stimulate the development and the activity of the microbial groups beneficial for the health of the individual.
  • compositions generally shown by the term "symbiotic”.
  • said composition additionally includes at least another probiotic bacterium.
  • said composition further includes at least a pharmacologically active substance.
  • compositions of the present invention proved useful preferably for the prevention and/or treatment of the following pathologies:
  • compositions include a mixture consisting of the following three bacterial species: Bifidobacterium lactis, Lactobacillus casei subsp. rhamnosus, Lactobacillus plan tarum.
  • particularly preferred bacterial strains belonging to said mixture of three bacterial species are resulted those selected from:
  • compositions of the present invention further include at least a substance having prebiotic properties.
  • Said prebiotic includes carbohydrates which are not digested and absorbed by the organism, namely fructo-oligosaccharides (or FOS), short-chain fructo-oligosaccharides, inulin, isomalt-oligosaccharides, pectins, galacto-oligosaccharides (or GOS), arabinogalactan, xylo-oligosaccharides (or XOS), chitosan-oligosaccharides (or COS'), glucanmannan, beta-glucans, Konjac, guar, arabic, xanthan gums, modified and resistant starches, polydextrose, D-tagatose.
  • FOS fructo-oligosaccharides
  • short-chain fructo-oligosaccharides inulin
  • isomalt-oligosaccharides inulin
  • pectins galacto-oligosaccharides
  • GOS galacto-oligosaccharides
  • Particularly preferred prebiotics are the short-chain fructo-oligosaccharides (for simplicity shown hereinbelow as FOSs-c.c.); said FOSs-c.c. are not digestable glucides, generally obtained by the conversion of the beet sugar and including a saccharose molecule to which three glucose molecules are bonded.
  • compositions of the present invention further include, in addition to the characterizing mixture, consisting of the three bacterial species above-defined, at least another probiotic bacterium.
  • said additional probiotic is selected among.the following bacterial species:
  • compositions of the present invention further include at least a pharmacologically active substance, so as to be able to perform a combined action to that exerted by said active substances.
  • such associations are revealed synergic, accordingly allowing the use of relatively low doses of pharmaceutical active substance, with a considerable decrease of the possible side effects induced by the administration of the drug alone.
  • Preferred pharmacologically active substances are, for example, selected from:
  • composition of the invention are preferably formulated in admixture with appropriate excipients, such as carriers, lubricants, dispersers, flavourings, sweeteners, stabilizers, preservatives, antioxidants, additives, such as amino acids, vitamins, enzymes, generally used in the formulation and the pharmaceutical art.
  • excipients such as carriers, lubricants, dispersers, flavourings, sweeteners, stabilizers, preservatives, antioxidants, additives, such as amino acids, vitamins, enzymes, generally used in the formulation and the pharmaceutical art.
  • starch such as those of mandarin, grapefruit, strawberry, bilberry, all fruits, saccharose, glucose, acesulfame, aspartame, ascorbic acid, parabens, glutamine, arginine, superoxide dismutase, glutathione.
  • fragrances such as those of mandarin, grapefruit, strawberry, bilberry, all fruits, saccharose, glucose, acesulfame, aspartame, ascorbic acid, parabens, glutamine, arginine, superoxide dismutase, glutathione.
  • compositions of the present invention are those for oral administration.
  • Typical preferred embodiments are, for example, capsules, beads, solutions or suspensions ready to drink, powders or granulates sachets (to be suspended or dissolved in water or non-carbonated and non-alcoholic beverages at the time of use) or similar forms, tablets, effervescent formulations.
  • compositions of the prevent invention can also be formulated in a coated, lacquered, encapsulated or microencapsulated form, so as to be gastroresistant.
  • Said composition can also be formulated in a controlled-release form, so as to selectively release the active substances in the intestinal tract, particularly in the colon.
  • the freeze-drying of said strains is carried out by using techniques and equipments generally employed in the freeze-drying processes of pharmaceutical and/or food compositions.
  • the compositions of the present invention are prepared in a traditional way by using, depending on the type of formulation that one wishes to prepare, preparative techniques known to the skilled in the pharmaceutical sector.
  • a granular formulation to be suspended or dissolved in water at the time of use, will be prepared by intimately mixing the components of the composition (active substances, co-adjuvants, excipients), reducing them to the desired granulometry and moisture degree, before packing them in single dose sealed sachets.
  • a controlled-release composition will be, for example, prepared by microencapsulating or microcoating the microgranulated mixture of the substances constituting the formulation with opportune mixtures of biocompatible polymers (such as, for example, Eudragit of different type and structure) resistant to the gastric juices of the stomach and able to release said components after a proper residence time in the gastrointestinal tract, or at pH values typical of the colon.
  • biocompatible polymers such as, for example, Eudragit of different type and structure
  • the microencapsulated mixture thus obtained will be, for example, used for the preparation of tablets, capsules or beads, depending on the selected commercial kind of presentation.
  • the bacterial species constituting the mixture of probiotic bacteria characterizing the present invention are present in a mutual weight ratio between 0.1:10 to 10:1, preferably in a mutual weight ratio between 0.5:1 to 2:1, more preferably in a mutual weight ratio of about 1:1.
  • said mixture of probiotic bacteria consists of the three bacterial species Bifidobacterium lactis, Lactobacillus casei subsp. Rhamnosus, Lactobacillus plantarum, said bacterial species are preferably present in a weight ratio of 1:1:1.
  • the additional probiotic if any, is present in a weight ratio between 0:1 to 100:1, with respect to the total quantitative of the bacterial species of said mixture; preferably, in a weight ratio between 2:1 to 15:1; more preferably, from 5:1 to 10:1.
  • the additional probiotic if any, is present in a weight ratio between 0:1. to 10:1, with respect to the total quantity of the bacterial species of said mixture; preferably, in a weight ratio from 0.5:1 to 3:1.
  • Each single bacterial species of said mixture of probiotic bacteria of the present invention is present in a concentration between 1 ⁇ 10 6 CFU(UFC)/dose to 1 ⁇ 10 12 CFU(UFC)/dose; preferably, from 1 ⁇ 10 9 CFU(UFC)/dose to 1 ⁇ 10 11 CFU(UFC)/dose.
  • a granulate for oral use, packed in single dose sachets to be dissolved in water before the intake is prepared.
  • compositions of the invention are given hereinbelow.
  • composition A Composition A
  • compositions of the present invention may also contain one or more pharmacologically active substances.
  • Said pharmacologically active substances can opportunely be formulated in admixture with the other components of the composition, such that they can be taken with a single administration.
  • Said pharmacologically active substances can also be formulated in a discrete packages, so as to allow an independent administration (if necessary also in different times) of the components, however such that the synergic effect is maintained, depending on the requirements of the patient.
  • independent packages are arranged, containing the composition of the present invention and the pharmacologically active substance/s, respectively.
  • the discrete packages above-mentioned are then introduced in a proper kit for allowing the patient to sequentially or separately take them, so as to benefit of a opportunely coordinated therapy depending on its own requirements.
  • kits as the one above-mentioned can contain a number of sachets, or capsules, for the oral administration of the compositions of the present invention, in combination with a proper number of doses of antibiotic and/or multivitaminic complex and/or mucolytic, sufficient for a week of therapy.
  • composition A of the present invention In a perspective study, conducted in double-blind randomized against placebo, the ability of the composition A of the present invention of improving the organism protection and restoring a normal state of health thereof towards the respiratory infections has been evaluated.
  • the study has involved the enrolment of 237 subjects, of which 122 treated with the preparation A and 115 treated with placebo.
  • the mean age of the two different samples was 35.8 (with standard deviation 15.3 years) and 34.1 (with standard deviation 16.3 years).
  • the qualitative and quantitative dosage of the secretion at the mucosal level of the secretory IgA has been carried out, before, during and for 30 days after the administration of the composition A.
  • the analytical determination of the secretory IgA in the salivary samples of the subjects treated with the composition A has pointed out an increasing production of the IgAs starting from the 5 th -6 th day from the beginning of the treatment, increase which has lasted up to about 4-14 days from the suspension of the same.
  • compositions of the present invention can also be used for the preparation of a medicament for preventing and fighting infections caused by influenza.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Claims (15)

  1. Utilisation d'une composition comprenant un mélange de bactéries probiotiques pour la préparation d'un médicament :
    (i) pour la prévention et/ou le traitement thérapeutique des pathologies et/ou infections respiratoires ; ou
    (ii) pour le traitement thérapeutique des pathologies respiratoires avec amélioration et/ou régularisation simultanées de la fonctionnalité intestinale de l'organisme compromise par les pathologies respiratoires ; ou
    (iii) pour la prévention et la lutte contre les infections causées par la grippe, caractérisée en ce que :
    - ladite composition comprend au moins une fibre prébiotique qui est choisie parmi : les fructo-oligosaccharides, les fructo-oligosaccharides à courte chaîne, l'inuline, les isomalto-oligosaccharides, les pectines, les galacto-oligosaccharides, l'arabinogalactane, les xylo-oligosaccharides, les chitosane-oligosaccharides, le glucanemannane, les bêta-glucanes, les gommes Konjac, guar, arabique, de xanthane, les amidons modifiés et résistants, le polydextrose, le D-tagatose, et en ce que
    - ledit mélange consiste en les trois espèces bactériennes suivantes : Bifidobacterium lactis, Lactobacillus casei ssp. rhamnosus et Lactobacillus plantarum.
  2. Utilisation selon la revendication 1 où les souches bactériennes appartenant auxdites espèces bactériennes sont choisies parmi :
    Bifidobacterium lactis, ID n. LMG P-21384;
    Lactobacillus casei ssp. rhamosus, ID n. DSM 16605;
    Lactobacillus plantarum, ID n. LMG P-21021 ;
    Lactobacillus plantarum, ID n. LMG P-21020 ;
    Lactobacillus plantarum, ID n. LMG P-21022 ;
    Lactobacillus plantarum, ID n. LMG P-21023.
  3. Utilisation selon l'une quelconque des revendications précédentes où ladite composition comprend en outre au moins un probiotique choisi parmi les espèces bactériennes : Bifidobacterium adolescentis, Bifidobacterium angulatum, Bifidobacterium animalis, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium catenulatum, Bifidobacterium denticolens, Bifidobacterium dentium, Bifidobacterium gallicum, Bifidobacterium infantis, Bifidobacterium inopinatum, Bifidobacterium longum, Bifidobacterium pseudocatenulatum, Enterococcus faecium, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus casei ssp. paracasei, Lactobacillus delbrueckii ssp. bulgaricus, Lactobacillus fermentum, Lactobacillus GG, Lactobacillus pentosus, Lactobacillus salivarius, Saccharomyces boulardi, Streptococcus thermophilus, Lactococcus lactis ssp. lactis, Lactococcus lactis ssp. diacetylactis; ledit probiotique est choisi de préférence parmi les souches bactériennes suivantes:
    Lactobacillus acidophilus, ID n. LMG P-21381;
    Lactobacillus casei ssp. paracasei, ID n. LMG P-21380;
    Lactobacillus pentosus, ID n. LMG P-21019;
    Lactobacillus delbrueckii ssp. bulgaricus, ID n. DSM 16607;
    Lactobacillus delbrueckii ssp. bulgaricus, ID n. DSM 16606.
  4. Utilisation selon l'une quelconque des revendications précédentes où ladite composition comprend en outre au moins une substance pharmacologiquement active, ladite substance pharmacologiquement active étant directement présente en mélange avec les autres composants de ladite composition ou étant formulée et conditionnée séparément de ceux-ci.
  5. Composition destinée à être utilisée dans la prévention et/ou le traitement thérapeutique des pathologies et/ou infections respiratoires comprenant un mélange de bactéries probiotiques consistant en les trois espèces bactériennes suivantes : Bifidobacterium lactis, Lactobacillus casei ssp. rhamnosus, Lactobacillus plantarum, ladite composition comprend en outre au moins une fibre prébiotique qui est choisie parmi : les fructo-oligosaccharides, les fructo-oligosaccharides à courte chaîne, l'inuline, les isomalto-oligosaccharides, les pectines, les galacto-oligosaccharides, l'arabinogalactane, les xylo-oligosaccharides, les chitosane-oligosaccharides, le glucanemannane, les bêta-glucanes, les gommes Konjac, guar, arabique, de xanthane, les amidons modifiés et résistants, le polydextrose, le D-tagatose.
  6. Composition destinée à être utilisée selon la revendication 5 où la prévention et/ou le traitement thérapeutique est présent avec une amélioration et/ou régularisation simultanées de la fonctionnalité intestinale de l'organisme.
  7. Composition destinée à être utilisée selon l'une quelconque des revendications 5-6 où les souches bactériennes appartenant auxdites espèces bactériennes sont choisies parmi :
    Bifidobacterium lactis, ID n. LMG P-21384;
    Lactobacillus casei ssp. rhamnosus, ID n. DSM 16605;
    Lactobacillus plantarum, ID n: LMG P-21021;
    Lactobacillus plantarum, ID n. LMG P-21020;
    Lactobacillus plantarum, ID n. LMG P-21022;
    Lactobacillus plantarum, ID n. LMG P-21023.
  8. Composition destinée à être utilisée selon l'une quelconque des revendications 5-7 où ladite composition comprend au moins un probiotique choisi parmi les espèces bactériennes : Bifidobacterium adolescentis, Bifidobacterium angulatum, Bifidobacterium animalis, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium catenulatum, Bifidobacterium denticolens, Bifidobacterium dentium, Bifidobacterium gallicum, Bifidobacterium infantis, Bifidobacterium inopinatum, Bifidobacterium longum, Bifidobacterium pseudocatenulatum, Enterococcus faecium, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus casei ssp. paracasei, Lactobacillus delbrueckii ssp. bulgaricus, Lactobacillus fermentum, Lactobacillus GG, Lactobacillus pentosus, Lactobacillus salivarius, Saccharomyces boulardi, Streptococcus thermophilus, Lactococcus lactis ssp. lactis, Lactococcus lactis ssp. diacetylactis; ledit probiotique est choisi de préférence parmi les souches bactériennes :
    Lactobacillus acidophilus, ID n. LMG P-21381;
    Lactobacillus casei ssp. paracasei, ID n. LMG P-21380;
    Lactobacillus pentosus, ID n. LMG P-21019;
    Lactobacillus delbrueckii ssp. bulgaricus, ID n. DSM 16607;
    Lactobacillus delbrueckii ssp. bulgaricus, ID n. DSM 16606.
  9. Composition destinée à être utilisée selon l'une quelconque des revendications 5-8 où ladite composition comprend en outre au moins une substance pharmacologiquement active, ladite substance pharmacologiquement active étant directement présente en mélange avec les autres composants de ladite composition ou étant formulée et conditionnée séparément de ceux-ci.
  10. Composition destinée à être utilisée selon l'une quelconque des revendications 5-9 où lesdites trois espèces bactériennes dudit mélange sont présentes dans un rapport en masse mutuel entre 0,1 : 1 et 10 : 1 ; de préférence dans un rapport en masse mutuel entre 0,5 : 1 et 2 : 1 ; de préférence encore dans un rapport d'environ 1 : 1.
  11. Composition destinée à être utilisée selon l'une quelconque des revendications 5-10 où chaque espèce bactérienne individuelle est dosée en une quantité entre 1.106 CFU (UFC)/dose et 1.1012 CFU (UFC)/dose ; de préférence de 1.109 CFU (UFC)/dose à 1.1011 CFU (UFC)/dose.
  12. Composition destinée à être utilisée selon la revendication 5 où ledit prébiotique est présent dans un rapport en masse entre 0 : 1 et 100 : 1, par rapport à la quantité totale desdites trois espèces bactériennes ; de préférence dans un rapport en masse entre 2 : 1 et 15 : 1 ; de préférence encore de 5 : 1 à 10 : 1.
  13. Composition destinée à être utilisée selon l'une quelconque des revendications 5-12 comprenant des granulés à usage oral, contenant :
    a) 0,1 g de Bifidobacterium lactis ID n. LMG P-21384, à une concentration de 1.1011 CFU/g de souche bactérienne, égale à 2.109 CFU/g de composition ;
    b) 0,1 g de Lactobacillus casei subsp. rhamnosus ID n. DSM 16605, à une concentration de 1.1011 CFU/g de souche bactérienne, égale à 2.109 CFU/g de composition ;
    c) 0,1 g Lactobacillus plantarum ID n. LMG P-21020, à une concentration de 1.1011 CFU/g de souche bactérienne, égale à 2.109 CFU/g de composition ;
    d) FOS-c.c. : 3 g ;
    e) glucose : 1,7 g.
  14. Kit comprenant, comme composants :
    - au moins une composition selon l'une quelconque des revendications 5-13 ;
    - au moins une substance pharmacologiquement active choisie parmi les antibiotiques, les anti-inflammatoires, les immunomodulateurs, les mucolytiques, les antispasmodiques et les vitamines ;
    lesdits composants étant conditionnés séparément, pour l'administration indépendante desdits composants.
  15. Composition destinée à être utilisée selon les revendications 5-13 où la composition est pour prévenir et combattre les infections causées par la grippe.
EP05793656A 2004-11-16 2005-10-05 Composition a base de bacteries probiotiques et son utilisation en vue de prevenir et/ou de traiter des pathologies et/ou des infections respiratoires et d'ameliorer la fonctionnalite intestinale Active EP1773361B2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL05793656T PL1773361T5 (pl) 2004-11-16 2005-10-05 Kompozycje oparte na bakteriach probiotycznych i ich zastosowanie w profilaktyce i/lub leczeniu patologii i/lub zakażeń układu oddechowego oraz poprawie funkcji jelit

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT002189A ITMI20042189A1 (it) 2004-11-16 2004-11-16 Composizione a base di batteri probiotici e suo uso nella prevenzione e-o nel trattamento di patologie e-o infezioni respiratorie e nel miglioramento della funzionalita' intestinale
PCT/IB2005/003214 WO2006054135A1 (fr) 2004-11-16 2005-10-05 Composition a base de bacteries probiotiques et son utilisation en vue de prevenir et/ou de traiter des pathologies et/ou des infections respiratoires et d’ameliorer la fonctionnalite intestinale

Publications (3)

Publication Number Publication Date
EP1773361A1 EP1773361A1 (fr) 2007-04-18
EP1773361B1 EP1773361B1 (fr) 2009-07-15
EP1773361B2 true EP1773361B2 (fr) 2012-09-26

Family

ID=35677517

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05793656A Active EP1773361B2 (fr) 2004-11-16 2005-10-05 Composition a base de bacteries probiotiques et son utilisation en vue de prevenir et/ou de traiter des pathologies et/ou des infections respiratoires et d'ameliorer la fonctionnalite intestinale

Country Status (15)

Country Link
US (1) US9233130B2 (fr)
EP (1) EP1773361B2 (fr)
JP (1) JP2008520640A (fr)
KR (1) KR101228608B1 (fr)
CN (1) CN101031313B (fr)
BR (1) BRPI0517273B8 (fr)
DE (1) DE602005015451D1 (fr)
DK (1) DK1773361T4 (fr)
ES (1) ES2329390T5 (fr)
HK (1) HK1110510A1 (fr)
IT (1) ITMI20042189A1 (fr)
PL (1) PL1773361T5 (fr)
PT (1) PT1773361E (fr)
RU (1) RU2418063C2 (fr)
WO (1) WO2006054135A1 (fr)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10322151B2 (en) 2015-06-15 2019-06-18 4D Pharma Research Limited Compositions comprising bacterial strains
US10391130B2 (en) 2015-06-15 2019-08-27 4D Pharma Research Limited Compositions comprising bacterial strains
US10391128B2 (en) 2015-11-23 2019-08-27 4D Pharma Research Limited Compositions comprising bacterial strains
US10456444B2 (en) 2014-12-23 2019-10-29 4D Pharma Research Limited Pirin polypeptide and immune modulation
US10471108B2 (en) 2015-11-20 2019-11-12 4D Pharma Research Limited Compositions comprising bacterial strains
US10485830B2 (en) 2016-12-12 2019-11-26 4D Pharma Plc Compositions comprising bacterial strains
US10493112B2 (en) 2015-06-15 2019-12-03 4D Pharma Research Limited Compositions comprising bacterial strains
US10500237B2 (en) 2015-06-15 2019-12-10 4D Pharma Research Limited Compositions comprising bacterial strains
US10583158B2 (en) 2016-03-04 2020-03-10 4D Pharma Plc Compositions comprising bacterial strains
US10610550B2 (en) 2015-11-20 2020-04-07 4D Pharma Research Limited Compositions comprising bacterial strains
US10610548B2 (en) 2016-07-13 2020-04-07 4D Pharma Plc Compositions comprising bacterial strains
US10736926B2 (en) 2015-06-15 2020-08-11 4D Pharma Research Limited Compositions comprising bacterial strains
US10744166B2 (en) 2015-11-23 2020-08-18 4D Pharma Research Limited Compositions comprising bacterial strains
US10851137B2 (en) 2013-04-10 2020-12-01 4D Pharma Research Limited Polypeptide and immune modulation
US10987387B2 (en) 2017-05-24 2021-04-27 4D Pharma Research Limited Compositions comprising bacterial strain
US11007233B2 (en) 2017-06-14 2021-05-18 4D Pharma Research Limited Compositions comprising a bacterial strain of the genus Megasphera and uses thereof
US11013773B2 (en) 2011-07-14 2021-05-25 4D Pharma Research Limited Lactic acid bacterial strains
US11123379B2 (en) 2017-06-14 2021-09-21 4D Pharma Research Limited Compositions comprising bacterial strains
US11123378B2 (en) 2017-05-22 2021-09-21 4D Pharma Research Limited Compositions comprising bacterial strains
US11224620B2 (en) 2016-07-13 2022-01-18 4D Pharma Plc Compositions comprising bacterial strains
US11266698B2 (en) 2011-10-07 2022-03-08 4D Pharma Research Limited Bacterium for use as a probiotic for nutritional and medical applications
US11723933B2 (en) 2014-12-23 2023-08-15 Cj Bioscience, Inc. Composition of bacteroides thetaiotaomicron for immune modulation

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20042189A1 (it) 2004-11-16 2005-02-16 Anidral Srl Composizione a base di batteri probiotici e suo uso nella prevenzione e-o nel trattamento di patologie e-o infezioni respiratorie e nel miglioramento della funzionalita' intestinale
EP1973406B1 (fr) 2005-12-28 2014-03-12 Advanced Bionutrition Corporation Véhicule de délivrance pour bactéries probiotiques, comprenant une matrice sèche en polysaccharides, saccharides et polyols sous forme de verre
JP5896589B2 (ja) * 2006-10-02 2016-03-30 デュポン ニュートリション バイオサイエンシーズ エーピーエス 疾病の罹患率及び持続期間を減少する使用のためのプロバイオティクス
WO2008071930A1 (fr) * 2006-12-11 2008-06-19 Danisco A/S Composition
CA2695366C (fr) 2007-08-03 2016-10-04 Shaklee Corporation Systeme de complement nutritionnel
US9763989B2 (en) 2007-08-03 2017-09-19 Shaklee Corporation Nutritional supplement system
WO2009021585A1 (fr) * 2007-08-13 2009-02-19 Dsm Ip Assets B.V. Bactéries probiotiques pour réduire l'occurrence de symptômes d'infections hivernales
US9055763B2 (en) * 2007-10-11 2015-06-16 Dupont Nutrition Biosciences Aps Probiotics for use in relieving symptoms associated with gastronitestinal disorders
ITMI20072260A1 (it) 2007-12-03 2009-06-04 Anidral Srl Una composizione a base di batteri probiotici in associazione con un prebiotico e suo uso nella prevenzione e/o nel trattamento di patologie e/o infezioni respiratorie e nel miglioramento della funzionalita intestinale.
US20090280099A1 (en) * 2008-05-07 2009-11-12 Bachman Stephen E Nasopharyngeal inoculate of probiotics and prebiotics for treatment of respiratory infections
JP5426850B2 (ja) * 2008-08-19 2014-02-26 株式会社日清製粉グループ本社 インフルエンザワクチンのアジュバント
KR101001767B1 (ko) 2008-11-04 2010-12-15 주식회사한국야쿠르트 항 인플루엔자 바이러스 효능을 갖는 락토바실러스 루테리 에이취와이7501 및 이를 유효성분으로 함유하는 제품
RU2011124506A (ru) 2008-11-17 2012-12-27 Эссум Аб Фармацевтический препарат, содержащий комбинацию штаммов streptococcus и штаммов lactobacillus
WO2010103132A1 (fr) * 2009-03-10 2010-09-16 Hero España, S.A. Isolement, identification et caractérisation de souches ayant une activité probiotique à partir de fèces de nourrissons alimentés exclusivement avec du lait maternel
ES2643148T3 (es) 2009-05-26 2017-11-21 Advanced Bionutrition Corporation Composición en polvo seco estable que comprende microorganismos biológicamente activos y/o materiales bioactivos y métodos de producción
IT1397566B1 (it) * 2009-05-27 2013-01-16 Probiotical Spa Lactobacillus pentosus produttore di batteriocine, composizioni alimentari e farmaceutiche contenenti lo stesso e relativo uso
WO2011044934A1 (fr) * 2009-10-14 2011-04-21 Probiotical S.P.A Souches de bactéries probiotiques permettant l'hydrolyse de fibres prébiotiques et compositions symbiotiques de celles-ci
US20110123677A1 (en) * 2009-11-25 2011-05-26 Pepsico, Inc. High acid beverage products and methods to extend probiotic stability
FI20096400A0 (fi) * 2009-12-28 2009-12-28 Suomen Punainen Risti Veripalv Veriryhmästatuksen käyttö I
AR080073A1 (es) 2010-01-28 2012-03-14 Advanced Bionutrition Corp Composicion vitrea seca que comprende un material bioactivo
US9504750B2 (en) 2010-01-28 2016-11-29 Advanced Bionutrition Corporation Stabilizing composition for biological materials
IT1398553B1 (it) * 2010-03-08 2013-03-01 Probiotical Spa Composizione comprendente batteri probiotici per il trattamento di patologie associate con le alterazioni del sistema immunitario.
WO2011148219A1 (fr) * 2010-05-28 2011-12-01 Compagnie Gervais Danone Souches probiotiques destinées à être utilisées dans l'amélioration du système nerveux entérique
CL2010001124A1 (es) * 2010-10-14 2011-01-21 Univ De Concepcion 50% Ma Loreto Ormeno 50% Alimento funcional probiotico que comprende cepas viables de lactobacillus sp.; uso de dicho alimento funcional para contrarestar los efectos colaterales de la quimioterapia.
GB201110095D0 (en) * 2011-06-15 2011-07-27 Danisco Method of treatment
ITRM20110475A1 (it) * 2011-09-09 2013-03-10 Probiotical Spa Ceppi di batteri lattici e/o bifido batteri, opzionalmente addizionati di n-acetilcisteina e/o lisozima microincapsulato gastroprotetto, aventi attivita' di inibizione/riduzione della crescita di differenti biotipi di e.coli, incluso e.coli o157:h7 e
ITRM20110477A1 (it) * 2011-09-09 2013-03-10 Giovanni Mogna Composizione comprendente n-acetilcisteina e/o lisozima microincapsulato gastroprotetto in associazione con batteri probiotici in grado di ripristinare l'effetto barriera proprio dello stomaco che viene perso durante il trattamento farmacologico dell
EP2802333B1 (fr) * 2012-01-13 2020-03-11 Chr. Hansen A/S Lactobacillus rhamnosus et bifidobacterium animalis subsp. lactis pour une utilisation dans la prévention ou le traitement des infections des voies respiratoires supérieures
KR101381794B1 (ko) * 2012-04-10 2014-04-07 씨제이제일제당 (주) 타가토스 및 프로바이오틱 유산균을 함유하는 신바이오틱 식품 조성물
KR101398977B1 (ko) * 2012-11-14 2014-05-27 대구가톨릭대학교산학협력단 락토바실러스 카세이 유산균주 배양용 d-타가토오스 함유 배지 및 d-타가토오스첨가 요구르트의 제조방법
JP6349095B2 (ja) * 2013-01-31 2018-06-27 ハイスキー食品工業株式会社 こんにゃく素材および希少糖の組み合わせ食品
CN103798392B (zh) * 2014-03-07 2015-12-30 内蒙古伊利实业集团股份有限公司 具有缓解咽喉部炎症功效的益生菌食品组合物及食品
CN105055438A (zh) * 2015-07-21 2015-11-18 珲春市神怡菌业生物科技开发有限公司 一种具有改善胃肠道功能的香菇多糖益生元组合物
MY194231A (en) 2015-07-29 2022-11-23 Advanced Bionutrition Corp Stable dry probiotic compositions for special dietary uses
ITUB20153106A1 (it) * 2015-08-13 2017-02-13 Probiotical Spa Composizione di batteri lattici per uso nel trattamento delle infezioni causate da Propionibacterium acnes e in particolare per l'acne
ITUB20159330A1 (it) 2015-12-22 2017-06-22 Roelmi Hpc S R L Composizioni probiotiche e loro uso
KR101749222B1 (ko) * 2016-01-04 2017-06-21 주식회사 카브 젖산균을 유효성분으로 포함하는 인플루엔자 바이러스 예방 및 치료용 조성물
CN106177188A (zh) * 2016-08-02 2016-12-07 马南行 一种用于女性抑菌平衡的益生菌组合物及其制备方法
US11179426B2 (en) * 2016-12-29 2021-11-23 Kibow Biotech, Inc. Composition and method for maintaining healthy kidney function
CN108295098A (zh) * 2018-02-02 2018-07-20 云南中京国建投资有限公司 一种辅助降血糖的合生元组合物及其制剂与应用
WO2019227414A1 (fr) * 2018-05-31 2019-12-05 深圳华大生命科学研究院 Composition et ses applications
KR101932955B1 (ko) 2018-06-14 2018-12-27 주식회사한국야쿠르트 장내 균총 개선용 프로바이오틱스 조성물
TW202015712A (zh) * 2018-07-03 2020-05-01 學校法人北里研究所 用以抑制流感之重症化的抗流感病毒劑
CN109432136A (zh) * 2018-10-31 2019-03-08 张志澎 一种益生菌组合制剂及其制备方法和应用
CN110055185B (zh) * 2018-12-25 2020-12-29 江南大学 一株具有抗流感能力的短双歧杆菌及其应用
CN109576185B (zh) 2018-12-26 2020-07-03 江南大学 一种具有抗流感能力的益生菌混合制剂及其应用
CN111544456A (zh) * 2019-05-15 2020-08-18 农绍汉 一种益生菌配方及其应用
CN110051702A (zh) * 2019-06-06 2019-07-26 广东才俊创展商务服务有限公司 一种防治手足口病、流感的益生菌配方
KR102328744B1 (ko) * 2019-10-08 2021-11-22 한국식품연구원 락토바실러스 플란타럼 균주를 유효성분으로 포함하는 호흡기 질환 개선용 조성물
CN110946990B (zh) * 2019-12-16 2023-05-23 天津瑞普生物技术股份有限公司 一种禽用呼吸道微生态喷雾制剂及其应用
CN111529703B (zh) * 2020-06-17 2023-09-15 湖南循天然营养有限公司 一种组合物及其制备方法与在制备免疫佐剂中的应用
CN112056399A (zh) * 2020-06-28 2020-12-11 武汉康复得生物科技股份有限公司 一种增强免疫力的益生菌组合物及其应用
WO2022103321A2 (fr) * 2020-11-12 2022-05-19 Synbiotics Ab Composition symbiotique
TW202302128A (zh) * 2021-03-26 2023-01-16 香港中文大學 微生物提高疫苗效力的用途
CN114657100B (zh) * 2022-04-01 2023-07-25 江南大学 一株能够缓解流感病毒感染小鼠病理特征的戊糖乳杆菌及其应用
CN115025132B (zh) * 2022-06-09 2024-01-30 康永波 一种合生元组合物及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997034615A1 (fr) † 1996-03-20 1997-09-25 The University Of New South Wales Renforcement de la colonisation microbienne du tractus gastro-intestinal
EP0904784A1 (fr) † 1997-09-22 1999-03-31 N.V. Nutricia Préparation nutritionnelle probiotique
WO2000033854A1 (fr) † 1998-12-09 2000-06-15 N.V. Nutricia Preparation contenant des oligosaccharides et des probiotiques

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6241983B1 (en) 1994-10-28 2001-06-05 Metagenics, Inc. Bacteria-and fiber-containing composition for human gastrointestinal health
JP4064481B2 (ja) 1996-10-11 2008-03-19 ハウスウェルネスフーズ株式会社 免疫賦活剤
US6379663B1 (en) * 1997-08-21 2002-04-30 New Zealand Dairy Board Immunity enhancing lactic acid bacteria
WO2001097821A1 (fr) * 2000-06-19 2001-12-27 Mucoprotec Pty Ltd Immunotherapie ou traitement de l'infection bacterienne ou virale a la surface des muqueuses avec des probiotiques et compositions utilisees a cet effet
FI110668B (fi) * 2000-06-20 2003-03-14 Aboatech Ab Oy Probioottien käyttö atooppisten sairauksien primaariseen ehkäisyyn
GB2369777B (en) 2000-10-05 2004-10-27 St Ivel Ltd Food products with antimicrobial lactic acid bacteria
FI109602B (fi) * 2001-01-25 2002-09-13 Valio Oy Probioottiyhdistelmä
DE20202562U1 (de) 2002-02-19 2002-05-23 Orthomol Pharmazeutische Vertr Mikronährstoffkombinationsprodukt mit Pro- und Prebiotika
ITMI20020399A1 (it) * 2002-02-28 2003-08-28 Ct Sperimentale Del Latte S P Composizioni dietetiche e/o farmaceutiche per uso umano e/o animale abase di preparati microbici probiotici
US20050074442A1 (en) 2002-03-13 2005-04-07 Natarajan Ranganathan Compositions and methods for augmenting kidney function
EP2336294A3 (fr) 2002-07-22 2014-07-02 Agtech Products, Inc. Souches de Lactobacillus et leurs utilisations
BRPI0418986A (pt) 2004-08-05 2007-12-11 Anidral Srl cepas bacterianas bifidobacterium produtoras de ácido fólico, formulações e seus usos
ITMI20042189A1 (it) 2004-11-16 2005-02-16 Anidral Srl Composizione a base di batteri probiotici e suo uso nella prevenzione e-o nel trattamento di patologie e-o infezioni respiratorie e nel miglioramento della funzionalita' intestinale
WO2007125558A1 (fr) 2006-05-03 2007-11-08 Anidral S.R.L. Composition symbiotique comprenant des polysaccharides non digestibles et des bifidobacteries qui les metabolisent et ses utilisations
ITMI20072260A1 (it) 2007-12-03 2009-06-04 Anidral Srl Una composizione a base di batteri probiotici in associazione con un prebiotico e suo uso nella prevenzione e/o nel trattamento di patologie e/o infezioni respiratorie e nel miglioramento della funzionalita intestinale.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997034615A1 (fr) † 1996-03-20 1997-09-25 The University Of New South Wales Renforcement de la colonisation microbienne du tractus gastro-intestinal
EP0904784A1 (fr) † 1997-09-22 1999-03-31 N.V. Nutricia Préparation nutritionnelle probiotique
WO2000033854A1 (fr) † 1998-12-09 2000-06-15 N.V. Nutricia Preparation contenant des oligosaccharides et des probiotiques

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ALVAREZ-OLMOS ET AL.: "Probiotic Agents and Infectious Diseases: A Modern Perspective on a Traditional Therapy", CLINICAL INFECTIOUS DISEASES, vol. 32, 2001, pages 1567 - 1576 †
HATAKA ET AL.: "Effect of long term consumption of probiotic milk on infections in children attending day care centres: double blind, randomised trial", BMJ, vol. 322, 2 June 2001 (2001-06-02), pages 1 - 5 †
http://www.gnpd.com DarmoPro Supplement 12 dec 2003 †
OUWEHAND ET AL.: "The mucus binding of Bifidobacterium lactis Bb12 is enhanced in the presence of Lactobacillus GG and Lact. delbrueckii subsp. bulgaricus", LETTERS IN APPLIED MICROBIOLOGY, vol. 30, 2000, pages 10 - 13 †
ROLLER ET AL.: "Prebiotic Inulin Enriched with Oligofructose in Combination with the Probiotics Lactobacillus rhamnosus and Bifidobacterium lactis Modulates Intestinal Immune Functions in Rats", THE JOURNAL OF NUTRITION, vol. 134, 2004, pages 153 - 156 †
ZOPPI ET AL.: "Modulation oh the Intestinal Ecosystem by Probiotics and Lactulose in Children During Treatment with Ceftriaxone", CURRENT THERAPEUTIC RESEARCH, vol. 62, no. 5, 14 March 2001 (2001-03-14), pages 418 - 435 †

Cited By (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11013773B2 (en) 2011-07-14 2021-05-25 4D Pharma Research Limited Lactic acid bacterial strains
US11266698B2 (en) 2011-10-07 2022-03-08 4D Pharma Research Limited Bacterium for use as a probiotic for nutritional and medical applications
US11414463B2 (en) 2013-04-10 2022-08-16 4D Pharma Research Limited Polypeptide and immune modulation
US10851137B2 (en) 2013-04-10 2020-12-01 4D Pharma Research Limited Polypeptide and immune modulation
US10456444B2 (en) 2014-12-23 2019-10-29 4D Pharma Research Limited Pirin polypeptide and immune modulation
US10973872B2 (en) 2014-12-23 2021-04-13 4D Pharma Research Limited Pirin polypeptide and immune modulation
US11723933B2 (en) 2014-12-23 2023-08-15 Cj Bioscience, Inc. Composition of bacteroides thetaiotaomicron for immune modulation
US11389493B2 (en) 2015-06-15 2022-07-19 4D Pharma Research Limited Compositions comprising bacterial strains
US10780134B2 (en) 2015-06-15 2020-09-22 4D Pharma Research Limited Compositions comprising bacterial strains
US10391130B2 (en) 2015-06-15 2019-08-27 4D Pharma Research Limited Compositions comprising bacterial strains
US11273185B2 (en) 2015-06-15 2022-03-15 4D Pharma Research Limited Compositions comprising bacterial strains
US10500237B2 (en) 2015-06-15 2019-12-10 4D Pharma Research Limited Compositions comprising bacterial strains
US11040075B2 (en) 2015-06-15 2021-06-22 4D Pharma Research Limited Compositions comprising bacterial strains
US10736926B2 (en) 2015-06-15 2020-08-11 4D Pharma Research Limited Compositions comprising bacterial strains
US10322151B2 (en) 2015-06-15 2019-06-18 4D Pharma Research Limited Compositions comprising bacterial strains
US10744167B2 (en) 2015-06-15 2020-08-18 4D Pharma Research Limited Compositions comprising bacterial strains
US11433106B2 (en) 2015-06-15 2022-09-06 4D Pharma Research Limited Compositions comprising bacterial strains
US10493112B2 (en) 2015-06-15 2019-12-03 4D Pharma Research Limited Compositions comprising bacterial strains
US10864236B2 (en) 2015-06-15 2020-12-15 4D Pharma Research Limited Compositions comprising bacterial strains
US11331352B2 (en) 2015-06-15 2022-05-17 4D Pharma Research Limited Compositions comprising bacterial strains
US10610550B2 (en) 2015-11-20 2020-04-07 4D Pharma Research Limited Compositions comprising bacterial strains
US10471108B2 (en) 2015-11-20 2019-11-12 4D Pharma Research Limited Compositions comprising bacterial strains
US11058732B2 (en) 2015-11-20 2021-07-13 4D Pharma Research Limited Compositions comprising bacterial strains
US10744166B2 (en) 2015-11-23 2020-08-18 4D Pharma Research Limited Compositions comprising bacterial strains
US10391128B2 (en) 2015-11-23 2019-08-27 4D Pharma Research Limited Compositions comprising bacterial strains
US10583158B2 (en) 2016-03-04 2020-03-10 4D Pharma Plc Compositions comprising bacterial strains
US10960031B2 (en) 2016-07-13 2021-03-30 4D Pharma Plc Compositions comprising bacterial strains
US10610549B2 (en) 2016-07-13 2020-04-07 4D Pharma Plc Composition comprising bacterial strains
US10610548B2 (en) 2016-07-13 2020-04-07 4D Pharma Plc Compositions comprising bacterial strains
US10967010B2 (en) 2016-07-13 2021-04-06 4D Pharma Plc Compositions comprising bacterial strains
US11224620B2 (en) 2016-07-13 2022-01-18 4D Pharma Plc Compositions comprising bacterial strains
US10898526B2 (en) 2016-12-12 2021-01-26 4D Pharma Plc Compositions comprising bacterial strains
US10543238B2 (en) 2016-12-12 2020-01-28 4D Pharma Plc Compositions comprising bacterial strains
US10485830B2 (en) 2016-12-12 2019-11-26 4D Pharma Plc Compositions comprising bacterial strains
US11123378B2 (en) 2017-05-22 2021-09-21 4D Pharma Research Limited Compositions comprising bacterial strains
US11376284B2 (en) 2017-05-22 2022-07-05 4D Pharma Research Limited Compositions comprising bacterial strains
US11382936B2 (en) 2017-05-22 2022-07-12 4D Pharma Research Limited Compositions comprising bacterial strains
US10987387B2 (en) 2017-05-24 2021-04-27 4D Pharma Research Limited Compositions comprising bacterial strain
US11007233B2 (en) 2017-06-14 2021-05-18 4D Pharma Research Limited Compositions comprising a bacterial strain of the genus Megasphera and uses thereof
US11123379B2 (en) 2017-06-14 2021-09-21 4D Pharma Research Limited Compositions comprising bacterial strains
US11660319B2 (en) 2017-06-14 2023-05-30 4D Pharma Research Limited Compositions comprising bacterial strains
US11779613B2 (en) 2017-06-14 2023-10-10 Cj Bioscience, Inc. Compositions comprising a bacterial strain of the genus Megasphera and uses thereof

Also Published As

Publication number Publication date
EP1773361A1 (fr) 2007-04-18
ES2329390T5 (es) 2013-02-11
DE602005015451D1 (de) 2009-08-27
PL1773361T3 (pl) 2010-05-31
ES2329390T3 (es) 2009-11-25
PL1773361T5 (pl) 2012-12-31
KR101228608B1 (ko) 2013-02-01
PT1773361E (pt) 2009-10-22
DK1773361T3 (da) 2009-11-16
BRPI0517273A (pt) 2008-10-07
US9233130B2 (en) 2016-01-12
DK1773361T4 (da) 2012-10-15
RU2418063C2 (ru) 2011-05-10
US20080107634A1 (en) 2008-05-08
BRPI0517273B8 (pt) 2021-05-25
JP2008520640A (ja) 2008-06-19
ITMI20042189A1 (it) 2005-02-16
CN101031313A (zh) 2007-09-05
WO2006054135A1 (fr) 2006-05-26
EP1773361B1 (fr) 2009-07-15
KR20070089130A (ko) 2007-08-30
BRPI0517273B1 (pt) 2020-11-03
RU2007106038A (ru) 2008-10-27
CN101031313B (zh) 2010-06-16
HK1110510A1 (en) 2008-07-18

Similar Documents

Publication Publication Date Title
EP1773361B2 (fr) Composition a base de bacteries probiotiques et son utilisation en vue de prevenir et/ou de traiter des pathologies et/ou des infections respiratoires et d'ameliorer la fonctionnalite intestinale
Stavropoulou et al. Probiotics in medicine: a long debate
JP6444358B2 (ja) ペディオコッカスを含有する医薬組成物および消化器症候群の症状を低減する方法
AU2017200343B2 (en) Prebiotic formulations and methods of use
RU2491081C2 (ru) Композиция на основе пробиотических бактерий совместно с пребиотиком и ее применение в предупреждении и/или лечении респираторных патологий и/или инфекций и для улучшения функций кишечника
US20200121740A1 (en) Pharmaceutical compositions containing pediococcus and methods for reducing the symptoms of gastroenterological syndromes
CN111528479A (zh) 一种缓解特应性皮炎功能的益生菌和益生元组合物及应用
Matsumoto et al. Anti-inflammatory metabolite production in the gut from the consumption of probiotic yogurt containing Bifidobacterium animalis subsp. lactis LKM512
Khursheed et al. Multifaceted role of synbiotics as nutraceuticals, therapeutics and carrier for drug delivery
KR20200112804A (ko) 프로바이오틱 및 프리바이오틱의 조합을 포함하는 약물 저항성 감염의 획득을 예방하거나 치료하기 위한 약학적 조성물
Mc Anto Antony et al. The Role of Gut Microbiome Supplementation in COVID-19 Management

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070131

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

17Q First examination report despatched

Effective date: 20070629

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 602005015451

Country of ref document: DE

Date of ref document: 20090827

Kind code of ref document: P

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: BOVARD AG PATENTANWAELTE

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: PROBIOTICAL S.P.A.

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20091014

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20090402554

Country of ref document: GR

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2329390

Country of ref document: ES

Kind code of ref document: T3

NLT1 Nl: modifications of names registered in virtue of documents presented to the patent office pursuant to art. 16 a, paragraph 1

Owner name: PROBIOTICAL S.P.A.

NLT2 Nl: modifications (of names), taken from the european patent patent bulletin

Owner name: PROBIOTICAL S.P.A.

Effective date: 20091007

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090715

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090715

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090715

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091115

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090715

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090715

REG Reference to a national code

Ref country code: FR

Ref legal event code: CA

Ref country code: FR

Ref legal event code: CD

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 436262

Country of ref document: AT

Kind code of ref document: T

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091015

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090715

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090715

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090715

PLAX Notice of opposition and request to file observation + time limit sent

Free format text: ORIGINAL CODE: EPIDOSNOBS2

26 Opposition filed

Opponent name: COMPAGNIE GERVAIS DANONE

Effective date: 20100415

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20091031

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090715

REG Reference to a national code

Ref country code: PL

Ref legal event code: T3

PLAF Information modified related to communication of a notice of opposition and request to file observations + time limit

Free format text: ORIGINAL CODE: EPIDOSCOBS2

PLBB Reply of patent proprietor to notice(s) of opposition received

Free format text: ORIGINAL CODE: EPIDOSNOBS3

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Owner name: PROBIOTICAL S.P.A.

Free format text: PROBIOTICAL S.P.A.#VIA MATTEI 3#28100 NOVARA (NO) (IT) -TRANSFER TO- PROBIOTICAL S.P.A.#VIA MATTEI 3#28100 NOVARA (NO) (IT)

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20091005

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100116

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090715

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090715

PLBP Opposition withdrawn

Free format text: ORIGINAL CODE: 0009264

REG Reference to a national code

Ref country code: AT

Ref legal event code: EEFA

Ref document number: 436262

Country of ref document: AT

Kind code of ref document: T

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

PUAH Patent maintained in amended form

Free format text: ORIGINAL CODE: 0009272

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: PATENT MAINTAINED AS AMENDED

27A Patent maintained in amended form

Effective date: 20120926

AK Designated contracting states

Kind code of ref document: B2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

REG Reference to a national code

Ref country code: CH

Ref legal event code: AEN

Free format text: AUFRECHTERHALTUNG DES PATENTES IN GEAENDERTER FORM

REG Reference to a national code

Ref country code: DK

Ref legal event code: T4

REG Reference to a national code

Ref country code: DE

Ref legal event code: R102

Ref document number: 602005015451

Country of ref document: DE

Effective date: 20120926

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: PL

Ref legal event code: T5

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20120402254

Country of ref document: GR

Effective date: 20121122

REG Reference to a national code

Ref country code: ES

Ref legal event code: DC2A

Ref document number: 2329390

Country of ref document: ES

Kind code of ref document: T5

Effective date: 20130211

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120926

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20201013

Year of fee payment: 16

Ref country code: IT

Payment date: 20201028

Year of fee payment: 16

Ref country code: PT

Payment date: 20201001

Year of fee payment: 16

Ref country code: GR

Payment date: 20201029

Year of fee payment: 16

Ref country code: AT

Payment date: 20201009

Year of fee payment: 16

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 436262

Country of ref document: AT

Kind code of ref document: T

Effective date: 20211005

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220405

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602005015451

Country of ref document: DE

Representative=s name: FRANKE & PARTNER PATENT- UND RECHTSANWAELTE IN, DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220506

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211005

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211005

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211031

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20231024

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20231030

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20231109

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20231017

Year of fee payment: 19

Ref country code: DK

Payment date: 20231018

Year of fee payment: 19

Ref country code: DE

Payment date: 20231016

Year of fee payment: 19

Ref country code: CH

Payment date: 20231102

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20231003

Year of fee payment: 19

Ref country code: BE

Payment date: 20231025

Year of fee payment: 19